EW News and Press, Edwards Lifesciences Corporation From 06/11/20

A Deeper Look Reveals New Concerns and Adds To Our Conviction Zynex (NASDAQ: ZYXI ) shares are up 150% year to date vs the Health Care Select SPDR ETF (NYSE: XLV) at -2%. We believe ZYXI's outperformance is a function of retail investor complacency combined with sell-side analyst careless...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 05/13/2020. Please visit our Tracking Ole Andreas Halvorsen...

IRVINE, Calif. , June 8, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received Chinese regulatory approval for the Edwards SAPIEN 3 ...

Introduction This article is a follow-up to a series of articles I recently wrote about how to avoid losses and how to profit from sentiment cycles. If you are already familiar with the strategy, feel free to skip down to the "Highlighted Stock of the Month" section and read from there. If y...

Edwards Lifesciences (NYSE: EW ) -66% . More news on: Edwards Lifesciences Corporation, Iterum Therapeutics plc, Novus Therapeutics, Inc., Stocks on the move, , Read more ...

This article is part of a series that provides an ongoing analysis of the changes made to Larry Robbins’ 13F portfolio on a quarterly basis. It is based on Robbins’ regulatory 13F Form filed on 05/15/2020. Please visit our Tracking Larry Robbins’ Glenview Capital Manage...

Quick Take Inari Medical ( NARI ) has filed to raise $110 million in an IPO of its common stock, per an amended registration statement . The company sells medical devices to treat vein thrombosis and pulmonary embolism conditions. NARI has produced enviable revenue growth and net profit...

IRVINE, Calif. , May 18, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received CE Mark for the Edwards PASCAL transcatheter val...

This article is part of a series that provides an ongoing analysis of the changes made to Kenneth Fisher’s 13F stock portfolio on a quarterly basis. It is based on Fisher Asset Management’s regulatory 13F Form filed on 04/28/2020. Please visit our Tracking Kenneth Fisher's Fis...

IRVINE, Calif. , May 7, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced updates from its annual meeting, in which Edwards' stockholders voted ...